ReleaseWire

ReportReserve’s new report, “Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications”, provides an expert insight into the global arthritis market and market forecast until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by ReportReserve’s team of industry experts. The report provides an in-depth analysis of the top four arthritis therapeutic indications which are osteoarthritis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape of the top companies in the market and an analysis of the key trends in mergers and acquisitions, and licensing agreements involving arthritis therapies.

GlobalData's clinical trial report, "Sarcomas Global Clinical Trials Review, H1, 2012" provides data on the Sarcomas clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sarcomas. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sarcomas. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

ReportReserve, the leading business intelligence provider, has released its latest research “Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution”. The report provides in-depth analysis of drivers and barriers that impact the global cardiovascular disorders market. The report analyzes the generics market for cardiovascular disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns are forecast until 2018 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

ReportReserve, the leading business intelligence provider, has released its latest research, “Pricing and Reimbursement in Brazil - Health Technology Assessment (HTA) Studies to Facilitate Setting of Ceiling Prices for New Drugs”. It provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in Brazil with key data, information and analysis of the pricing and reimbursement steps in the country. The report closely scrutinizes the major changes in pharmaceuticals-related pricing and reimbursement in Brazil.

ReportReserve, the leading business intelligence provider, has released its latest research “Drug Price Cuts in Top Five Countries of Europe - Tougher Reference Pricing Environment and Drug Price Freeze through 2013 Expected to Drive Down Healthcare Costs”. It provides a comprehensive overview of the healthcare systems as well as pricing in five European nations with a detailed analysis of the different regulatory mechanisms used in these countries. The report closely scrutinizes major changes in pricing for pharmaceuticals in these European nations in the recent past and their impact in the near future. The countries analyzed in the report are the UK, Germany, France, Spain and Italy.

BMI View: Brazil remains the most attractive emerging pharmaceutical market in the Americas due to its large population, strong consumer demand, increasing urbanisation and comparatively good drug regulatory environment. Many multinational pharmaceutical companies reported double digital growth during Q411. We expect foreign drugmakers to engage in more collaborations with local companies to capitalise on the rapid market growth and the government's incentives to promote the local industry.

GlobalData's pharmaceuticals report, "Afinitor (Pancreatic cancer) - Analysis and Forecasts to 2020" provides Afinitor sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2011-2020). The report also includes information on Pancreatic Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Lupus Nephritis Global Clinical Trials Review, H1, 2012" provides data on the Lupus Nephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lupus Nephritis . It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lupus Nephritis . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Tourette Syndrome Global Clinical Trials Review, H1, 2012" provides data on the Tourette Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Tourette Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Tourette Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The transfer of prescription digestive medicines to the self-medication market continued in France between the end of 2010 and 2011. After the switch of Pantoprazole with a dosage of 20mg per tablet at the end of 2009, Trimebutine 100mg was switched at the end of 2010. As a result, new brands were available within this category: Pantozol Control from Nycomed France, Pantoloc from Novartis Group France and Mopralpro from Bayer Sante Familiale, all of them proton pump inhibitors during 2010, but...

Anesthesia is a condition in which sensation is totally or partially blocked. This enables the patients to undergo medical procedures and surgery. Based on the applications (type of surgery or medical procedure) anesthetic drugs are broadly categorized into two types; i.e. local anesthetic drugs and general anesthetic drugs. Local anesthesia is a condition when sensation within a specific body part in inhibited, where as general anesthesia results in loss of consciousness and sensation.

GlobalData, the industry analysis specialist, has released its new report, "Obsessive Compulsive Disorder (OCD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Obsessive Compulsive Disorder Therapeutics market. The report identifies the key trends shaping and driving the global Obsessive Compulsive Disorder Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Obsessive Compulsive Disorder Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Anesthesia is a condition in which sensation is totally or partially blocked. This enables the patients to undergo medical procedures and surgery. Based on the applications (type of surgery or medical procedure) anesthetic drugs are broadly categorized into two types; i.e. local anesthetic drugs and general anesthetic drugs. Local anesthesia is a condition when sensation within a specific body part in inhibited, where as general anesthesia results in loss of consciousness and sensation.

GlobalData's clinical trial report, "Adenomas Global Clinical Trials Review, H1, 2012" provides data on the Adenomas clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Adenomas. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Adenomas. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's pharmaceuticals report, "Halaven (Breast cancer) - Analysis and Forecasts to 2020" provides Halaven sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2010-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - March 2012" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in February 2012. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

GBI Research, the leading business intelligence provider, has released its latest research "Oral Drug Delivery Market to 2017 - Out-licensing Proprietary Technologies for Proteins, Peptides and Small Molecules to Drive Revenue Growth". The report focuses on the current scenario of orally administered drugs. Key segment of orally administered drugs which are covered in the report include small molecules, proteins, peptides and vaccines. The oral drug delivery market is forecast to show increase in the forecast period (2010-2017) due to increase in demand for innovative oral drugs. The report analyses marketed oral drugs based on molecule type and indication. Pipeline drugs by molecule type are discussed in detail. The report analyses different types of nano-technology which will decide the future of orally administered drugs. Key drug delivery companies are profiled with their proprietary technologies, pipeline molecules and deals. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Growing economic concerns in the later part of 2011 in Europe and North America motivated organizations to rethink about their growth prospects for 2012. According to a World Bank projection in January 2012, world economic growth will be truncated to 2.5% in 2012 and 3.1% in 2013, as compared with a projection of 3.6% in June 2011, following the financial turmoil in Europe and weak growth prospects in emerging nations.

BMI View: Despite the threat of austerity measures and the government's focus on cost-containment within the pharmaceuticals and healthcare sector, as well as the impact of generic competition as a result of the patent cliff, we expect Germany to remain attractive to innovative drugmakers. In 2011, Germany's drug market was the fourth largest globally after the US, Japan and China. Furthermore, per-capita spending is high, there is a sizeable pensionable population and regulations are transparent - factors BMI believes will continue to bring in substantial income for companies operating in the country.

""Shionogi Inc.: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report"" contains in depth information and data about the company and its operations. The profile contains a company overview, business description, competitive benchmarking, SWOT analysis, mergers & acquisitions, key facts, information on products and services, details of locations and subsidiaries, plus information on key news events affecting the company.

GlobalData's pharmaceuticals report, "Taxotere (Breast Cancer) - Analysis and Forecasts to 2020" provides Taxotere sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Pharmaceuticals - Top 5 Emerging Markets Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the Top 5 Emerging markets (Brazil, China, India, Mexico and South Africa). The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

OTC Pharmaceuticals in Poland by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2011. This market covers analgesics, cough/col/flu, gastro-intestinal, dermatological, vitamins and minerals and other OTC pharmaceuticals. It excludes products which require prescriptions but includes pharmacy approved. Market size comprises sales through all retail channels including direct to consumer. Market size for OTC Pharmaceuticals in Poland is given in PLN with a minimum of five years' historical data. Market Forecast is provided for five years. Included with this snapshot is socio-economic data for Poland. Population, Consumer Price Index (CPI), Gross Domestic Product (GDP), Exchange Rates.

RxProfits has announced the launch of its new Rx affiliate program yesterday, RxProfits.com. The new program constitutes a first of its kind pharmacy affiliate service where participating affiliates enjoy the highest commissions in the Rx market (40%-50%) - unaffected by customer refunds; the finest quality of health products and conversion-oriented sites; custom white labels; how-to manuals and more.

“Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"